




















Takeda Oncology Pipeline

Beginning with patients' needs, we build our pipeline by identifying the most promising science and collaborate with leading teams around the globe to accelerate innovation. Our oncology R&D activities are focused on translating science into curative or transformative potential treatments by targeting tumor vulnerabilities and through novel strategies that leverage the power of innate immunity.

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

INVESTIGATIONAL THERAPY	PLATFORM	INVESTIGATIONAL INDICATION	PHASE	ADDITIONAL INFORMATION
Cabozantinib*	Targeted therapy	<i>Metastatic castration-resistant prostate cancer (JP)</i>	Phase 3 	Tyrosine kinase inhibitor including MET/AXL/VEGFR Cabozantinib is being developed in Japan in collaboration with Exelixis.
		<i>2L metastatic non-small cell lung cancer (JP)</i>	Phase 3 	
Ixazomib*	Proteasome inhibitor	<i>Maint. newly diagnosed multiple myeloma post-stem cell transplant (US, EU)</i>	Phase 3 	Proteasome inhibitor
		<i>Maint. newly diagnosed multiple myeloma without stem cell transplant (US, EU, CN)</i>	Phase 3 	
Mobocertinib*	Targeted therapy	<i>2L EGFR Exon20 insertion non-small cell lung cancer (CN)</i>	Filed 	Oral EGFR Exon20 tyrosine kinase inhibitor
		<i>2L EGFR Exon20 insertion non-small cell lung cancer (JP)</i>	Phase 3 	
		<i>1L EGFR Exon20 insertion non-small cell lung cancer</i>	Phase 3 	
Ponatinib*	Targeted therapy	<i>FL Ph+ acute lymphocytic leukemia (US)</i>	Phase 3 	BCR-ABL inhibitor Takeda shares development rights with Incyte Corp. (Europe, Turkey and Israel) and Otsuka Pharm. (Asia Pacific territories).
		<i>Pediatric Ph+ acute lymphoblastic leukemia</i>	Phase 1 	
Relugolix* (TAK-385)	Small molecule	<i>Prostate cancer (JP, Asian countries)</i>	Phase 3 	GnRH antagonist Relugolix is being developed in Japan and Asian countries in collaboration with Myovant Sciences, Inc.
Niraparib*	Targeted therapy	<i>Triple-negative breast cancer</i>	Phase 3 	PARP 1/2 inhibitor Niraparib is being developed in collaboration with GSK. Takeda has development and commercialization rights for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea and Taiwan.

INVESTIGATIONAL THERAPY	PLATFORM	INVESTIGATIONAL INDICATION	PHASE	ADDITIONAL INFORMATION
Modakafusp Alfa (TAK-573)	I-O cold-to-hot	<i>Multiple myeloma</i>	Phase 1/2 	Immune targeting attenuated cytokine Modakafusp alfa (TAK-573) was licensed from Teva Pharmaceuticals.
		<i>Solid tumors</i>	Phase 1/2 	
Subasumstat (TAK-981)	I-O cold-to-hot	<i>Solid tumors</i>	Phase 1/2 	SUMOylation inhibitor
		<i>Non-Hodgkin lymphoma</i>	Phase 1/2 	
		<i>Multiple myeloma</i>	Phase 1/2 	
TAK-007	I-O redirected immunity	<i>B-cell malignancies</i>	Phase 2 	CD19 CAR NK TAK-007 is being developed in collaboration with The University of Texas MD Anderson Cancer Center.
TAK-186	I-O redirected immunity	<i>Solid tumors</i>	Phase 1/2 	EGFR x CD3 targeting COBRA (COnditional Bispecific Redirected Activation) T cell engager immunotherapy
TAK-102	I-O redirected immunity	<i>Solid tumors</i>	Phase 1 	GPC3 targeted CAR-T TAK-102 was licensed from Noile-Immune Biotech.
TAK-103	I-O redirected immunity	<i>Solid tumors</i>	Phase 1 	Mesothelin targeted CAR-T TAK-103 was licensed from Noile-Immune Biotech.
TAK-500	I-O cold-to-hot	<i>Solid tumors</i>	Phase 1 	Targeted STING agonist
TAK-676	I-O cold-to-hot	<i>Solid tumors</i>	Phase 1 	STING agonist
TAK-940	I-O redirected immunity	<i>B-cell malignancies</i>	Phase 1 	CD19-1XX CAR-T TAK-940 is being developed in collaboration with Memorial Sloan Kettering Cancer Center.
TAK-280	I-O redirected immunity	<i>Solid tumors</i>	Phase 1/2 	B7-H3 x CD3 targeting COBRA (COnditional Bispecific Redirected Activation) T cell engager immunotherapy

*Marketed products have received approval in one or more jurisdictions.

All programs have global development rights unless otherwise noted.

GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets

   @TakedaOncology

Learn more at [TakedaOncology.com](https://www.takedaoncology.com)

©2022 Takeda Pharmaceuticals U.S.A., Inc.



ONCOLOGY